1.. Background to the Development of Pemafibrate as the First SPPARM*α* in the World
====================================================================================

Fibrate development stemmed from the discovery of phenylethyl acetate, an ester that reduced lipids from agricultural chemical ingredients in the 1950s^[@bib1])^. Fibrates were subsequently developed, starting with clofibrate, which functioned as a lipid-lowering agent. However, fibrates\' mechanisms of action remained elusive for a long time. Elucidating the structure of peroxisome proliferator-activated receptor (PPAR)^[@bib2])^ and thereafter, PPAR subtype demonstrated that PPAR*α* was intimately involved in regulating lipid metabolism since it was associated with the transcription of genes involved in the reduction of serum triglycerides (TG) and increase in high-density lipoprotein (HDL) cholesterol (HDL-C). It was also clarified that fibrates act on PPAR*α* and elicit their biological effects^[@bib3],\ [@bib4])^. However, while activation of PPAR*α* by fibrates exhibited improved lipid levels, various off-target effects, such as deterioration in liver and kidney function test values, were observed, which were difficult to attenuate.

Several large-scale clinical trials using fibrates have previously been conducted. In the Helsinki Heart Study^[@bib5])^ and VA-HIT study^[@bib6])^ for gemfibrozil, it was confirmed, for the first time, that fibrates have a significant inhibitory effect on cardiovascular (CV) events, which were the primary endpoints of the trials. However, a report indicated that drug-drug interactions between gemfibrozil and some statins (cerivastatin) caused a high incidence of rhabdomyolysis in patients^[@bib7])^. In subsequent trials, such as the BIP study (bezafibrate)^[@bib8])^, FIELD study (fenofibrate)^[@bib9])^, and the ACCORD-lipid study (fenofibrate on top of simvastatin) ^[@bib10])^, primary endpoints could not be achieved, and the clinical efficacy of fibrates could not be reliably demonstrated. However, in a meta-analysis of fibrates^[@bib11])^, fibrates\' inhibitory effects on CV events were demonstrated, and the event inhibitory effect was shown for each test, particularly in analysis of the subclasses of patients with high TG and low HDL-C^[@bib12])^. On the other hand, the meta-analysis showed no significant reduction in the total mortality rate upon the administration of fibrates. Statin meta-analyses by the Cholesterol Treatment Trialists\' (CTT) Collaboration^[@bib13]--[@bib15])^ showed contrasting results, indicating that administration of statins significantly reduced the total mortality rate, but the aforementioned off-target effects of fibrates may have offset their efficacy.

In these circumstances, a novel notion of selective PPAR*α* modulator (SPPARM*α*) was proposed by Fruchart^[@bib16],\ [@bib17])^. The principle of SPPARM*α* action is shown in **[Fig. 1](#F1){ref-type="fig"}**. Multiple ligands with a variety of structures, including free fatty acids and fibrates, bind to PPAR*α*, inducing downstream, ligand-specific structural changes and responses upon association with ligand-specific cofactors. SPPARM*α* introduces the concept of a drug that selectively regulates transcription of genes involved in beneficial actions among the PPAR*α* target genes. Thus, it should have a better benefit-risk balance compared to the existing PPAR*α* agonists. Based on the concept of SPPARM*α*, Kowa Company, Ltd. developed pemafibrate (K-877, Parmodia^®^ tablet), while screening for a compound with potent PPAR*α* activity and high PPAR*α* selectivity. A 2-aminobenzoxazole ring was inserted into an existing fibric acid skeleton, the length of the carbon chain was modified, and a phenoxyalkyl group was introduced to enable synthesis of this drug as a highly active and selective PPAR*α* agonist^[@bib18])^. The PPAR*α* activation by pemafibrate was reported to be \> 2,500 times stronger than fenofibric acid, the active form of fenofibrate, making it an extremely selective PPAR*α* agonist (subtype-selectivity \> 5,000-fold for PPAR*γ*, and \> 11,000-fold for PPAR*δ*, respectively)^[@bib19],\ [@bib20])^ (**[Table 1](#T1){ref-type="table"}**).
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###### Activity of PPAR Agonists in Cell-Based Transactivation Assays

                                                                                Human receptor EC50 (µM)             
  ----------------------------------------------------------------------------- -------------------------- --------- -----------
  pemafibrate^[1)](#tf2){ref-type="table-fn"}^                                  0.00080                    4.3       9.0
  Wy-14643^[2)](#tf3){ref-type="table-fn"}^                                     5.0                        60        35
  clofibrate^[2)](#tf3){ref-type="table-fn"}^[\*](#tf1){ref-type="table-fn"}    55                         ∼500      Ia at 100
  fenofibrate^[2)](#tf3){ref-type="table-fn"}^[\*](#tf1){ref-type="table-fn"}   30                         300       Ia at 100
  bezafibrate^[2)](#tf3){ref-type="table-fn"}^                                  50                         60        20
  GW 9578^[2)](#tf3){ref-type="table-fn"}^                                      0.05                       1.0       1.4
  troglitazone^[2)](#tf3){ref-type="table-fn"}^                                 Ia                         0.55      Ia
  pioglitazone^[2)](#tf3){ref-type="table-fn"}^                                 Ia                         0.58      Ia
  rosiglitazone^[2)](#tf3){ref-type="table-fn"}^                                Ia                         0.043     Ia
  KRP-297^[2)](#tf3){ref-type="table-fn"}^                                      0.85                       0.083     9.1
  JTT-501^[2)](#tf3){ref-type="table-fn"}^[\*](#tf1){ref-type="table-fn"}       1.9                        0.083     Ia
  SB 213068^[2)](#tf3){ref-type="table-fn"}^                                    0.74                       0.066     Ia
  GI 262570^[2)](#tf3){ref-type="table-fn"}^                                    0.45                       0.00034   Ia
  GW 1929^[2)](#tf3){ref-type="table-fn"}^                                      Ia                         0.0062    Ia
  GW 7845^[2)](#tf3){ref-type="table-fn"}^                                      3.5                        0.00071   Ia
  GW 0207^[2)](#tf3){ref-type="table-fn"}^                                      Ia                         0.044     Ia
  L-796449^[2)](#tf3){ref-type="table-fn"}^                                     0.0041                     0.0052    0.0079
  L-165041^[2)](#tf3){ref-type="table-fn"}^                                     10                         5.5       0.53
  GW 2433^[2)](#tf3){ref-type="table-fn"}^                                      0.17                       2.5       0.19

Ia = Inactive at 10µM or the concentration indicated.

Data are presented for the active metabolites.
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Pemafibrate (R-36 form in the literature) showed an equivalent or better TG-lowering activity, compared to fenofibric acid in rats, without increasing the liver weight^[@bib18])^. Transcriptome analysis using rats and human liver cells, also suggested that the induced and suppressed gene groups differ between pemafibrate and fenofibrate^[@bib21])^. Pemafibrate has a Y-shaped structure, unlike conventional fibrates (**[Fig. 2](#F2){ref-type="fig"}**). The ligand-binding domain in PPAR*α* is Y-shaped, and when the Y-shaped pemafibrate binds with the entire cavity area, like a key in a lock, the structure of PPAR*α* undergoes specific conformational changes due to the strong interaction, and a new region is exposed. This region is the PPAR*α* co-activator, which strongly activates PPAR*α* by binding with peroxisome proliferator-activated receptor-*γ* coactivator 1*α* (PGC-1*α*). Studies suggest that, in addition to fibric acid, which is common to the conventional fibrates, a Y-shaped structure with suitably arranged aminobenzoxazole and dimethoxybenzene is ideal for SPPARM*α*^[@bib22])^. Thus, pemafibrate has an ideal structure that corresponds to the concept of SPPARM*α*.

![Structural Conformation of Pemafibrate Favoring Better Selectivity for PPAR*α*](jat-26-389-g002){#F2}

Pemafibrate was launched in Japan in June 2018, ahead of the rest of the world, and is expected to have a superior benefit-risk balance compared to the conventional fibrates. The Japan Atherosclerosis Society, along with overseas evaluations, has positioned pemafibrate as a drug classified into the SPPARM*α* category, which is completely different from the fibrates (**[Table 2](#T2){ref-type="table"}**)^[@bib23])^.

###### Classification of Medications Used to Treat Dyslipidemia According to Their Efficacy

  Category                                                                          LDL-C    Non-HDL-C   TG     HDL-C   Major drug name
  --------------------------------------------------------------------------------- -------- ----------- ------ ------- ---------------------------------------------------------------------------------
  Statin                                                                            ↓↓∼↓↓↓   ↓↓∼↓↓↓      ↓      ---∼↑   Pravastatin, Simvastatin, Fluvastatin, Atorvastatin, Pitavastatin, Rosuvastatin
  Intestinal cholesterol transporter inhibitor (Cholesterol absorption inhibitor)   ↓↓       ↓↓          ↓      ↑       Ezetimibe
  Anion exchange resin                                                              ↓↓       ↓↓          ↑      ↑       Colestimide, Cholestyramine
  Probucol                                                                          ↓        ↓           ---    ↓↓      Probucol
  PCSK9 inhibitor                                                                   ↓↓↓↓     ↓↓↓↓        ↓∼↓↓   ---∼↑   Evolocumab, Alirocumab
  MTP inhibitor[\*](#tf4){ref-type="table-fn"}                                      ↓↓↓      ↓↓↓         ↓↓↓    ↓       Lomitapide
  Fibrate                                                                           ↑∼↓      ↓           ↓↓↓    ↑↑      Bezafibrate, Fenofibrate, Clinofibrate, Clofibrate
  Selective peroxisome proliferator-activated receptor *α* modulator (SPPARM*α*)    ↑∼↓      ↓           ↓↓↓    ↑↑      Pemafibrate
  Nicotinic acid derivative                                                         ↓        ↓           ↓↓     ↑       Niceritrol, Nicomol, Tocopheryl nicotinate
  N-3 polyunsaturated fatty acid                                                    ---      ---         ↓      ---     Ethyl icosapentate, Omega-3-acid ethyl ester

Applicable only to patients with homozygous FH.

↓↓↓↓∶ ≤ −50%, ↓↓↓∶−30%∼−50%, ↓↓∶−20%∼−30%, ↓∶−10%∼−20%, ↑∶10%∼20%, ↑↑∶20%∼30%, ---∶−10%∼10%

2.. Results of Clinical Trials of Pemafibrate
=============================================

2.1. Comparative Studies with Fenofibrate
-----------------------------------------

The results of clinical studies on pemafibrate in Japan were reviewed. The results of three Japanese clinical studies demonstrated the high efficacy of pemafibrate, compared to fenofibrate^[@bib24]--[@bib26])^. The TG-lowering action of 0.4 mg/day pemafibrate was greater than that of 100 mg/day (80 mg/day with tablet conversion), and 106.6 mg/day fenofibrate, respectively, and was equivalent to 200 mg/day fenofibrate (160 mg/day with tablet conversion) (**[Fig. 3](#F3){ref-type="fig"}**). The incidence of adverse events observed with pemafibrate administration was equivalent to placebo and was markedly lower than fenofibrate, with a particularly low proportion of adverse events related to kidney and liver function (**[Table 3](#T3){ref-type="table"}**). Previous reports have indicated that existing fibrates worsened kidney function test values, such as serum creatinine, cystatin C, and estimated glomerular filtration rate (eGFR)^[@bib27]--[@bib29])^. Pemafibrate exhibited a relatively significant lower elevation in serum creatinine and cystatin C, and a comparatively lower reduction in eGFR than those seen with fenofibrate, and less exacerbation in test values related to kidney function. It is well known that administration of fenofibrate elevates liver function test values, and the mechanism of action includes PPAR*α* activation^[@bib30])^. The liver function test values for alanine aminotransferase (ALT) and gamma-glutamyl transferase (*γ*-GT) did not show an elevation with pemafibrate when compared to fenofibrate; conversely, these values tended to decrease. This may be a characteristic clinical effect of the SPPARM*α*, pemafibrate.

![Effects of Pemafibrate on Serum Triglycerides Levels\
PEMA 0.05, pemafibrate 0.05 mg/day; PEMA 0.1, pemafibrate 0.1 mg/day; PEMA 0.2, pemafibrate 0.2 mg/day; PEMA 0.4, pemafibrate 0.4 mg/day; FF100, fenofibrate micronized capsule 100 mg/day; FF200, fenofibrate micronized capsule 200 mg/day; FF106.6, fenofibrate tablet 106.6 mg/day.\
The data are presented as the least squares mean ± standard error. (a) \*\*\**p* \< 0.001 vs. baseline. ^†††^*p* \< 0.001 vs. placebo (Dunnett). ^\#\#\#^*p* \< 0.001 vs. fenofibrate 100 mg. (b) In repeated measures ANCOVA (baseline as the covariate and weeks 8, 10, and 12 as repetition points). \*\*\**p* \< 0.001 vs. baseline. (c) In repeated measures ANCOVA (baseline as the covariate and weeks 8, 12, 16, 20, and 24 as repetition points). \*\*\**p* \< 0.001 vs. baseline. ^\#^*p* \< 0.05 vs. fenofibrate 106.6 mg.](jat-26-389-g003){#F3}

###### Incidence of Adverse Events by Pemafibrate and Fenofibrate

  Study                                                    Types                              Placebo   Pemafibrate   Fenofibrate                                           
  -------------------------------------------------------- ---------------------------------- --------- ------------- ------------- --------- --------- --------- --------- ---------
  **K-877-04**                                             Total                              17/36     21/37         12/37         18/38     16/39     21/37     \-        \-
  Ishibashi S, *et al.*^[1)](#tf5){ref-type="table-fn"}^                                      (47.2%)   (56.8%)       (32.4%)       (47.4%)   (41.0%)   (56.8%)             
  **K-877-09**                                             Total                              18/43     \-            15/45         49/128    34/85     36/85     \-        79/140
  Arai H, *et al.*^[2)](#tf6){ref-type="table-fn"}^                                           (41.9%)                 (33.3%)       (38.3%)   (40.0%)   (42.4%)             (56.4%)
                                                           Liver-related                      4/43      \-            2/45          3/128     7/85      13/85     \-        34/140
                                                                                              (9.3%)                  (4.4%)        (2.3%)    (8.2%)    (15.3%)             (24.3%)
                                                           Rhabdomyolysis-/myopathy-related   3/43      \-            1/45          2/128     2/85      3/85      \-        7/140
                                                           (7.0%)                                       (2.2%)        (1.6%)        (2.4%)    (3.5%)              (5.0%)    
  **K-877-17**                                             Total                              \-        \-            \-            28/73     37/74     \-        45/76     \-
  Ishibashi S, *et al.*^[3)](#tf7){ref-type="table-fn"}^                                                                            (38.4%)   (50.0%)             (59.2%)   
                                                           Liver-related                      \-        \-            \-            5/73      0/74      \-        30/76     
                                                                                                                                    (6.8%)                        (39.5%)   
                                                           Kidney-related                     \-        \-            \-            0/73      0/74      \-        3/76      \-
                                                                                                                                                                  (3.9%)    
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2.2. Effect of Pemafibrate on Lipid Metabolism
----------------------------------------------

High fasting TG levels are directly linked to increased TG-rich lipoproteins (TRL), such as chylomicrons (CM) derived from small intestines, very low-density lipoprotein (VLDL) derived from the liver, and their TG-hydrolyzed remnant lipoproteins (CM remnants, VLDL remnants (intermediate-density lipoprotein \[IDL\])). These remnant lipoproteins have proatherogenic properties^[@bib31],\ [@bib32])^. Increased TRL often increases small dense low-density lipoprotein (LDL), which strongly correlates with atherosclerosis, and reduces HDL-C. Administration of pemafibrate significantly reduces remnant lipoprotein cholesterol (RemL-C), non-HDL-C, Apolipoprotein B (ApoB), ApoB48, and ApoC3 levels. Furthermore, the results of the subfractions of LDL and HDL, evaluated by high performance liquid chromatography (HPLC) (Liposearch, Skylight Biotech, Tokyo, Japan), showed that dose-related reductions by pemafibrate were observed in small LDL particles while dose-dependent increases were demonstrated in small HDL particles^[@bib24])^.

A recent study reported that non-fasting TG levels are a better indicator of CV events than fasting TG^[@bib33])^. In Japan, it was also reported that non-fasting TG is one of the risk factors for coronary artery disease (CAD) similar to fasting TG^[@bib34])^. Postprandial hyperlipidemia, a metabolic condition with a delayed metabolism of CM remnants after eating, increases susceptibility to CV events, including CAD. Postprandial hyperlipidemia is characterized by 1) higher serum TG levels after meal, 2) the peak of serum TG concentration is delayed, and 3) failing to decline to the pre-meal levels even after 8 h^[@bib35])^. Pemafibrate (0.4 mg/day) was administered for four weeks in dyslipidemic patients. The effect of pemafibrate on postprandial hyperlipidemia was demonstrated by a reduction in TG, RemL-C, and ApoB-48 in both fasting and non-fasting states^[@bib36])^. Sairyo *et al.* reported that pemafibrate tended to inhibit the expression of *Npc1l1* and *Mttp* mRNA in the small intestine mucosa more strongly than fenofibrate in mice fed a high-fat diet (HFD)^[@bib37])^. Similarly, Takei *et al.* reported that pemafibrate inhibited the expression of cholesterol transporter *Npc1l1* and promoted expression of *Abca1* in the small intestine of *Ldlr*^-/-^ mice. These two actions were mediated by the activation of PPAR*α*^[@bib38])^. These reports suggest that pemafibrate may attenuate post-prandial hyperlipidemia, by repressive effects on CM synthesis and secretion processes, via suppression of cholesterol absorption by *Npc1l1*, in addition to PPAR*α* activation in the small intestines.

Pemafibrate is also believed to inhibit VLDL secretion from the liver by upregulating genes related to fatty acid *β*-oxidation^[@bib19],\ [@bib38])^, in addition to fibroblast growth factor 21 (FGF21). FGF21 is also known to be involved in fatty acid *β*-oxidation and is downstream of PPAR*α*^[@bib39],\ [@bib40])^. Furthermore, FGF21 is known to reduce VLDL secretion from the liver by regulating fatty acid uptake by adipose tissue^[@bib41])^. Pemafibrate increases FGF21 expression even at smaller doses^[@bib19],\ [@bib38],\ [@bib42])^, which may be one of the mechanisms that inhibits VLDL secretion.

Lipoprotein lipase (LPL) promotes the catabolism of CM secreted from the intestine and VLDL secreted from the liver. An increase in LPL activity that affects CM and VLDL catabolism has been demonstrated in animal studies upon pemafibrate administration^[@bib37],\ [@bib38])^. Increased LPL activity upon pemafibrate administration is linked to increased LPL synthesis due to the PPAR*α* activation. Furthermore, pemafibrate reduced ApoC3 levels, which inhibits LPL, and also downregulated angiopoietin-like 3 (Angptl3), which in turn suppresses LPL activity^[@bib19])^. Fibrates can also possibly affect ApoA5 levels due to PPAR*α* activation^[@bib43])^.

We have developed an algorithm for calculating the number of particles in 19 of the 20 lipoprotein fractions obtained from HPLC analysis data^[@bib44])^. The results of a sub-analysis from pemafibrate Phase 2 study^[@bib24])^ confirmed fewer small LDL particles which are involved in atherosclerosis and more small HDL particles which have a strong anti-atherosclerotic function^[@bib45])^. Reduced cholesterol efflux capacity (CEC) of HDL correlated with the presence of CAD, and CEC showed an inverse correlation to the risk of CV events^[@bib46])^. Thus, CEC is gaining attention as a new CAD risk factor. Smaller-sized HDLs are thought to have stronger CEC^[@bib47])^. We showed that administering pemafibrate 0.4 mg/day for 4 weeks to patients with dyslipidemia significantly increased the CEC from macrophages to HDL in the pemafibrate group as compared to the placebo group^[@bib36])^. In this study, the HDL-C, HDL3-C, pre*β*1HDL, and ApoA-1 levels increased in the pemafibrate group. Pemafibrate also increased FGF21 levels, which are known to increase the expression of ATP binding cassette transporter A1 (ABCA1) and ATP binding cassette transporter G1 (ABCG1), ABC proteins involved in the releasing cholesterol from macrophages^[@bib48])^ (**[Fig. 4](#F4){ref-type="fig"}**)^[@bib19],\ [@bib21],\ [@bib36]--[@bib38],\ [@bib49])^.

![Mechanism of Action of Pemafibrate on Lipoprotein Metabolism in the Liver, Small Intestine, and Macrophages\
ABCA1, ATP-binding cassette transporter A1; ABCG1, ATP-binding cassette transporter G1; ANGPTL3, angiopoietin-like 3; Apo, apolipoprotein; CE, cholesteryl ester; CM, chylomicron; FGF21, fibroblast growth factor 21; HDL, high-density lipoprotein; HDL-C, high-density lipoprotein cholesterol; IDL, intermediate-density lipoprotein; LDL, low-density lipoprotein; LDL-R, low-density lipoprotein receptor; LPL, lipoprotein lipase; LRP, low-density lipoprotein receptor-related protein; Npc1l1, niemann-pick c1-like 1; Remnant-R, remnant receptor; SR-BI, scavenger receptor class B type I; TG, triglyceride; TRL, triglyceride-rich lipoprotein; VLDL, very low-density lipoprotein.](jat-26-389-g004){#F4}

2.3. Effect of Co-administration of Pemafibrate and Statins
-----------------------------------------------------------

Two clinical studies of combined treatment with pemafibrate and statins have been reported^[@bib50])^. A 12-week administration of pemafibrate to patients with dyslipidemia taking pitavastatin, with a fasting TG of ≥ 200 mg/dL and a non-HDL-C of ≥ 150 mg/dL, reduced the fasting TG values by 6.9% in the placebo group, 46.1% in the 0.1 mg/day pemafibrate group, 53.4% in the 0.2 mg/day group, and 52.0% in the 0.4 mg/day group, respectively, demonstrating a superior fasting TG reducing activity of pemafibrate. In the long-term study, where 0.2--0.4 mg/day pemafibrate was administered for 24 weeks to patients with dyslipidemia (TG ≥ 200 mg/dL) treated with any of these statins; pravastatin, simvastatin, fluvastatin, atorvastatin, rosuvastatin, or pitavastatin, pemafibrate demonstrated stable TG reduction over the mentioned period. Furthermore, there was no significant increase in adverse effects or clinical concerns associated with pemafibrate compared to placebo in any of the studies. As seen in the studies not combined with statins, pemafibrate decreased liver function test values and had little effects on kidney function test values.

Combined treatment with fibrates and statins increases the risk of rhabdomyolysis, particularly in patients with compromised kidney function. There is a particularly high incidence of rhabdomyolysis in patients using a combination of gemfibrozil and cerivastatin, which was reported as a typical case of drugdrug interaction^[@bib7])^. As a result, the sale of cerivastatin worldwide was halted. One possible mechanism of the onset of rhabdomyolysis on co-administration of these two drugs is thought to be the inhibition of cerivastatin metabolism by gemfibrozil, thereby increasing cerivastatin exposure in patients. Drug interaction studies have been performed in healthy male volunteers with pemafibrate and high doses of various statins (pravastatin, simvastatin, fluvastatin, atorvastatin, pitavastatin, or rosuvastatin)^[@bib51])^. When pemafibrate was administered to healthy adults combined with various statins, there was no major change in C~max~ or areas under the curve in pemafibrate or in any of the statins. There was a decrease in the blood concentration of a single statin, simvastatin, and the simvastatin open acid form, but the HMG-CoA reductase inhibitory activity was still maintained. Hence, it has been confirmed that pemafibrate does not trigger drug interactions with statins.

2.4. Pemafibrate Administration to Patients with Impaired Kidney Function
-------------------------------------------------------------------------

Pemafibrate has a characteristic excretion route, mainly from the liver, with only 14.5% excretion in the urine^[@bib52])^. Pemafibrate is predominately metabolized in, and is almost exclusively excreted from, the liver. The main plasma metabolites are benzyl oxidized oxidant and a mixture of glucuronic acid conjugate and N-dealkylated dicarboxylic acid^[@bib53])^. The urinary excretion rate of unaltered pemafibrate is \< 0.5%, and almost all the metabolized compounds excreted in the urine show no activity as PPAR*α* agonists.

Pemafibrate exposure was not dependent on renal dysfunction severity^[@bib54])^. Long-term administration of pemafibrate was found to be effective and safe in patients with dyslipidemia, including patients with impaired kidney function, since there was no increase in blood concentrations of pemafibrate, even with repeated dosage^[@bib55])^. The main fibrates currently in use are bezafibrate and fenofibrate. These are renal excretory drugs, and increased blood concentration has been confirmed in patients with impaired renal function. Patients with high TG and low HDL-C, presenting a decreased kidney function, have been extremely difficult to treat because available drugs are limited. However, theoretically, pemafibrate may be safely administered to patients with decreased kidney function, as this drug is a SPPARM*α* and not excreted through the kidneys (**[Table 4](#T4){ref-type="table"}**). As stated above, pemafibrate may present an improved benefit-risk balance and can be considered to be a beneficial drug for patients with a limited ability to use conventional fibrates.

###### Major Excretion Route of SPPARM*α* and Fibrates, and Pharmacokinetics in Patients with Kidney Dysfunction

  Category    Major drug name   Major excretion route   Excretion into the urine
  ----------- ----------------- ----------------------- --------------------------------------------
  Fibrates    Clofibrate        Kidney                  95∼99%^[1)](#tf8){ref-type="table-fn"}^
              Clinofibrate      Liver                   ≤ 1%^[2)](#tf9){ref-type="table-fn"}^
              Bezafibrate       Kidney                  69.1%^[3)](#tf10){ref-type="table-fn"}^
              Fenofibrate       Kidney                  64%^[4)](#tf11){ref-type="table-fn"}^
              Gemfibrozil       Kidney                  70%^[5)](#tf12){ref-type="table-fn"}^
                                                        
  SPPARM*α*   Pemafibrate       Liver                   14.5% ⋇ ^[6)](#tf13){ref-type="table-fn"}^
                                                        ⋇ Active form: \< 0.5%

<https://pubchem.ncbi.nlm.nih.gov/compound/2796>. Accessed on 4 September 2018
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FDA Approved Drug Products, Parke-Davis, Division of Pfizer Inc., LOPID (Gemfibrozil Tablets, USP) \[package insert\]. NY, NY; April 2018. [https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event = overview.process&applno=018422](https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event = overview.process&applno=018422)

Hounslow N, Mair S, Suganami H and Nakamura M: Pemafibrate has high bioavailability and is principally excreted via the liver. Atherosclerosis Supplements, 2018; 32: 157 \[ISA2018 Abstract\]

2.5. Non-lipid Effects of Pemafibrate
-------------------------------------

Long-term administration of pemafibrate in patients with hypertriglyceridemia and type 2 diabetes has revealed lower fasting blood glucose and insulin levels compared to placebo group^[@bib56])^. A clinical study investigating the effect of pemafibrate on liver or peripheral insulin resistance using a hyperinsulinemiceuglycemic clamp^[@bib57])^ showed that pemafibrate significantly increased the rate of glucose uptake by the liver and improved insulin resistance. In mice with diet-induced obesity, pemafibrate not only reduced plasma TG, but was also expected to show metabolic effects such as inhibition of a HFD-induced weight gain, reduced plasma glucose and insulin, increased plasma FGF21, upregulation of genes related to thermogenesis and fatty acid oxidation, and improvement in obesity-induced metabolic abnormalities^[@bib42])^.

PPAR*α* knockout mice have been reported to exhibit phenotypes, such as severe fatty liver and steatohepatitis^[@bib58])^. Non-alcoholic steatohepatitis (NASH) patients had lower PPAR*α* expression in the liver^[@bib59])^, so PPAR*α* agonists have attracted attention as therapeutic agents for non-alcoholic fatty liver disease (NAFLD). However, while a number of reports suggest fibrates\' efficacy on NAFLD in animal studies^[@bib60]--[@bib62])^, its efficacy in clinical practice has been relatively unclear. One possible reason for poor clinical performance of fibrates may be associated with the adverse reactions, leading to liver and kidney dysfunction which may eventually lower the drugs\' efficacy. Therefore, we believe that SPPARM*α*, pemafibrate, can be a proof-of-concept drug to improve metabolic abnormalities better than existing fibrates, and can be expected to have an enhanced therapeutic effect on NASH/NAFLD. Pemafibrate improves liver function and histological findings in a number of rodent NASH/NAFLD models, including the suppression of fatty liver, inflammation, ballooning and fibrosis^[@bib63],\ [@bib64])^. Pemafibrate is believed to help improve NAFLD pathology by regulating genes that govern lipid transport in and out of the liver, *β*-oxidation, and by improving energy metabolism by upregulation of uncoupling protein 3 (UCP3) genes. In clinical practice, administration of pemafibrate reduces serum ALT, *γ*-GT, alkaline phosphatase (ALP), and total bilirubin, especially in patients whose liver function values exceeded the baseline reference values^[@bib65])^. These results suggest that pemafibrate may be effective for treating fatty liver, NASH/NAFLD, or even primary biliary cholangitis (PBC).

A Phase 2 study evaluating the therapeutic effect of pemafibrate on NAFLD is currently underway in Japan (ClinicalTrials.gov Identifier: NCT03350165). A pharmacokinetic study is also being implemented for pemafibrate in patients with PBC (JapicCTI-173728).

3.. Effect of Pemafibrate on Atherosclerosis
============================================

The main aim of treating dyslipidemia with pemafibrate is to prevent CV events. There are a number of reports that suggest an anti-atherosclerotic effect of pemafibrate. In human apoE2 knock-in mice which are fed a high-fat, high-cholesterol diet (Western Diet), pemafibrate administration reduced plasma total cholesterol, non-HDL-C and TG, and increased HDL-C. These mice also showed a downregulation in the transcription levels of small intestine ApoB mRNA, and liver ApoC-III mRNA, which demonstrated that pemafibrate (0.1 mg/kg body weight) exerted a superior effect equivalent to or better than fenofibrate treatment (250 mg/kg body weight). The area of atherosclerotic lesions was reduced further with 1 mg/kg pemafibrate treatment than with 250 mg/kg fenofibrate. The mRNA expression of vascular cell adhesion molecule-1 (VCAM-1), F4/80 and interleukin-6 (IL-6) at the lesion site was also inhibited significantly, indicating pemafibrate\'s anti-inflammatory effect^[@bib49])^. Administration of pemafibrate in LDL receptor knockout mice resulted in reduced liver ApoC3 levels, and, in the event of vascular disorders, there was reduced neointimal formation and suppressed macrophage accumulation. This, in turn, is believed to inhibit CD64-positive cells in monocytes, inhibit M1 polarization in IFN*γ*-stimulated macrophages, and increase NcoR1 2 levels (co-repressor of proinflammatory cytokines), which decrease with IFN*γ* stimulation^[@bib66],\ [@bib67])^. Administration of pemafibrate to LDL knockout mice fed a high-fat, high-cholesterol diet markedly reduced the lipid deposition area within the aortic sinus. Furthermore, the MOMA-2 positive area was reduced by 33% compared to the control, suggesting inhibited macrophage infiltration into the plaques^[@bib68])^. Pemafibrate (30 mg/day) was administered for 35 days in hyperlipidemia cardiovascular stent model pigs, with the stent indwelled on day 7, and the animals were observed for the following 28 days. The results showed the neointimal formation volume was reduced by 26.3% in the pemafibrate group compared to the control group, and pemafibrate also inhibited the accumulation of inflammatory cells caused by the placement of the stent^[@bib69])^. Furthermore, balloon failure was induced in an LDL receptor knockout pig model two weeks after starting administration of pemafibrate. Eight weeks later, there was a significant reduction in macrophage ratio in the plaques in the pemafibrate group compared to the control group. The mRNA levels of c-Jun, nuclear factor kappa-B (NF-~*κ*~B) and matrix metalloproteinase-9 (MMP-9) also showed a significant reduction in the pemafibrate group as compared to the control group^[@bib70])^. These results suggest that pemafibrate has a more potent anti-atherosclerotic effect than fenofibrate.

Fibrates inhibit the expression of fibrinogen by activating PPAR*α*, and reduced fibrinogen level is a downstream effect common to all fibrates^[@bib71])^. The results of the BIP study, a large-scale clinical study on bezafibrate, reported fibrinogen is a predictor of mortality^[@bib72])^, which suggests that reduction of fibrinogen levels is one of the mechanisms whereby fibrates inhibit CV events. Pemafibrate has also been confirmed to have a superior fibrinogen reducing effect than fenofibrate^[@bib24])^.

4.. Future Expectations
=======================

The large-scale clinical study PROMINENT (Pemafibrate to Reduce cardiovascular OutcoMes by reducing triglycerides IN diabetic patiENTs), implemented to verify the effect of pemafibrate on inhibiting CV events in humans, is currently underway in 24 countries worldwide, including Japan, the U.S., the U.K., and Russia. The PROMINENT study aims to recruit 10,000 patients with type 2 diabetes who also have high TG/low HDL-C, with LDL cholesterol (LDL-C) controlled by drugs, including statins ([ClinicalTrials.gov](ClinicalTrials.gov) Identifier: NCT03071692 **[Table 5](#T5){ref-type="table"}**)^[@bib73])^.

###### Study Design of PROMINENT^[@bib73])^

  Patients               Type 2 diabetes with fasting TG ≥ 200 mg/dL and \< 500 mg/dL and HDL-C ≤ 40 mg/dL
  ---------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Primary Endpoint       4-component composite endpoint of 1) nonfatal myocardial infarction,2) nonfatal ischemic stroke,3) hospitalization for unstable angina requiring unplanned coronary revascularization, or4) cardiovascular death
  Treatment              Pemafibrate 0.4 mg/day (BID) vs Placebo
  Design                 Multi-regional, randomized, double-blind, placebo-controlled
  Estimated Enrollment   10,000 patients
  Estimated Period       March 2017---May 2022
  Directors              Paul Ridker, Aruna Pradhan (CCVDP & The Brigham and Women\'s Hospital)

Fibrates are effective against diabetic microvascular disorders, as shown in a number of large-scale clinical studies^[@bib74])^. In the FIELD study, where fenofibrate was administered to patients with type 2 diabetes, the results demonstrated efficacy in the treatment of diabetic retinopathy and diabetic nephropathy, including a reduced number of photocoagulation procedures required for diabetic retinopathy and amelioration of microalbuminuria^[@bib9],\ [@bib75])^. Administration of pemafibrate in db/db mice was reported to reduce NAD(P)H oxidase-4 (NOX4) expression associated with inhibiting protein kinase C (PKC) activity, reduce the diacylglycerol content in the kidneys, and reduce kidney damage by oxidative stress^[@bib76])^. Thus, pemafibrate should possess an anti-inflammatory and anti-oxidative function and, hence, have a favorable effect on diabetic microvascular disorders. In the PROMINENT study, the PROMINENT-Eye Ancillary Study ([ClinicalTrials.gov](ClinicalTrials.gov) Identifier: NCT03345901) is also in progress as a sub-study to evaluate pemafibrate\'s effect in inhibiting the progression of retinopathy. The study is expected to clarify whether pemafibrate has an effect on diabetic microvascular disorders. Since pemafibrate is a novel class of drug SPPARM*α* distinct from fibrates, it may have quite new efficacy on diabetic complications. Diabetic patients usually have reduced eGFR due to nephropathy; however, conventional fibrates could not be used because they are renally metabolized. Pemafibrate can be used for diabetic patients with nephropathy. Thus, it could become an essential drug for diabetic patients.

Serum TG levels \> 1000 mg/dL increase the risk of acute pancreatitis. Pemafibrate was almost never administered to patients with TG levels \> 1000 mg/dL during developmental clinical studies. There are two studies currently underway in Europe and the U.S. in patients with severe hypertriglyceridemia ([ClinicalTrials.gov](ClinicalTrials.gov) Identifier: NCT03011450, NCT03001817). It may be necessary to verify pemafibrate\'s efficacy in such patients with severe hypertriglyceridemia in Japan, which has lower rates of fat consumption than western countries.

Conclusions
===========

Pemafibrate is the world\'s first SPPARM*α*, developed based upon a completely new concept, which shows distinct differences from the conventional fibrates and exhibits high selectivity for PPAR*α*. Pemafibrate is not excreted by the kidneys and is mainly metabolized by the liver. Pemafibrate has no drug-drug interactions with statins. It has a better benefit-risk balance than the existing fibrates and is considered to be a safer drug for patients with limited response to existing fibrates, including patients taking statins, and patients with compromised kidney functions. The SPPARM*α* pemafibrate was developed in Japan ahead of the rest of the world, and is expected to have a significant efficacy as a new therapeutic option for dyslipidemia as well as diabetic complications and liver diseases.
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